STRATA Skin Sciences, Inc. (SSKN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

NeurAxis, Inc.

Singular Genomics Systems, Inc.

Nortech Systems, Inc.

NeuroOne Medical Technologies Corp.

Sientra, Inc.

PetVivo Holdings, Inc.

Acutus Medical, Inc.

STRATA Skin Sciences, Inc.

Modular Medical, Inc.

Check-Cap Ltd.

SmileDirectClub, Inc.

Why is STRATA Skin Sciences, Inc. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -21.88% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -4.08
ROCE(HY) Lowest at -207.19%
NET SALES(Q) At USD 6.93 MM has Fallen at -15.62%
CASH AND EQV(HY) Lowest at USD 13.04 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -89.11%, its profits have fallen by -10.7%

Below par performance in long term as well as near term

Along with generating -89.11% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is STRATA Skin Sciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

STRATA Skin Sciences, Inc.

-90.47%

-0.62

145.02%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.16%

EBIT Growth (5y)

-21.88%

EBIT to Interest (avg)

-4.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

2.89

Sales to Capital Employed (avg)

1.47

Tax Ratio

1.82%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

23.43%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.23

EV to EBIT

-1.57

EV to EBITDA

-6.38

EV to Capital Employed

1.03

EV to Sales

0.33

PEG Ratio

Dividend Yield

ROCE (Latest)

-65.84%

ROE (Latest)

-598.40%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -4.79 MM

RAW MATERIAL COST(Y)

Fallen by -0.49% (YoY

EPS(Q)

Highest at USD -0.36

-16What is not working for the Company

ROCE(HY)

Lowest at -207.19%

NET SALES(Q)

At USD 6.93 MM has Fallen at -15.62%

CASH AND EQV(HY)

Lowest at USD 13.04 MM

DEBT-EQUITY RATIO (HY)

Highest at 702.89 %

OPERATING PROFIT MARGIN(Q)

Lowest at -13.08 %

NET PROFIT(Q)

At USD -2.31 MM has Fallen at -20.12%

Here's what is working for STRATA Skin Sciences, Inc.

EPS

Highest at USD -0.36

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by -0.49% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for STRATA Skin Sciences, Inc.

Net Sales

At USD 6.93 MM has Fallen at -15.62%

over average net sales of the previous four periods of USD 8.21 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Operating Profit Margin

Lowest at -13.08 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Net Profit

At USD -2.31 MM has Fallen at -20.12%

over average net sales of the previous four periods of USD -1.92 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 13.04 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 702.89 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio